JF
EIGR

Jump Financial’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Jump Financial’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,370
Closed -$259K – 2081
2022
Q2 		$259K Buy
1,370
+270
+25% +$54.4K 0.01% 1143
2022
Q1 		$274K Buy
1,100
+337
+44% +$53.3K 0.01% 1117
2021
Q4 		$119K Buy
+763
New +$148K 0.01% 1205

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Jump Financial's EIGR Position: Q3 2022 in Review

Jump Financial sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2022, closing a stake of 1,370 shares — an estimated $259K sold.

Jump Financial first reported a position in EIGR in Q4 2021 and held it in 3 quarters. The position peaked at $274K in Q1 2022. 92 funds tracked by Wall St. Rank hold EIGR as of Q3 2022.

  • Jump Financial reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • Jump Financial sold 1,370 Eiger BioPharmaceuticals, Inc. shares in Q3 2022, an estimated $259K.
  • Jump Financial first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2021 and held it in 3 quarters.
  • Jump Financial's Eiger BioPharmaceuticals, Inc. position peaked at $274K in Q1 2022.
  • 92 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2022.

Based on Jump Financial's 13F filing for Q3 2022, filed 7 Nov 2022.